RENAL CELL CARCINOMA

This study tests whether giving a combination of two drugs (axitinib and a PD-1 antibody) before surgery can help prevent kidney cancer from coming back. About 298 patients with high-risk kidney cancer will either receive the drug combo before surgery or have surgery alone. The g…

This study tests an experimental drug called AZD6750, designed to help the immune system fight cancer. It is for adults with advanced solid tumors (like melanoma, lung, or breast cancer) that have spread. The trial will first find the safest dose, then test if it works alone or w…

This study looks at whether a blood test can detect leftover cancer cells after kidney cancer surgery. Patients with no signs of cancer in the blood will skip standard immunotherapy, while those with signs will receive it. The goal is to see if this approach helps people live lon…

This study tests whether the drug casdatifan, alone or with zimberelimab, can safely shrink kidney tumors before surgery. It involves 32 adults with clear cell renal cell carcinoma who are scheduled for kidney removal. The goal is to see if these drugs reduce tumor size and are s…

This study tests a daily pill called olaparib in people with advanced kidney cancer that has certain gene mutations (like BAP-1 or BRCA). The goal is to see if the drug can shrink tumors or keep them stable for at least six months. About 20 adults who have already tried other tre…

This study tests whether two drugs, tivozanib and nivolumab, can help control advanced non-clear cell kidney cancer. About 48 adults with this rare cancer type will receive the combination. The main goal is to see how safe and tolerable the treatment is.

This study tests an experimental oral drug called Alintegimod combined with standard immunotherapies (ipilimumab and nivolumab) in people with advanced solid tumors like melanoma, lung, kidney, or liver cancer who have already tried other treatments. The goal is to see if the com…

This study tests whether a higher dose of the drug cabozantinib can help people with advanced kidney cancer whose cancer kept growing on the standard dose. About 18 adults whose cancer had been controlled by cabozantinib for at least 6 months before progressing will receive a hig…

This study tests a new drug called HLX17 to see if it works like the approved cancer drug Keytruda. It is for people who have had surgery for lung cancer, melanoma, or kidney cancer. The study will compare how the drugs move through the body, their safety, and how well they work.…

This study is for people with kidney cancer that cannot be removed with surgery. It uses a very focused type of radiation called stereotactic body radiotherapy (SBRT) to treat the tumor. The main goal is to see if this treatment can stop the cancer from growing for at least 2 yea…

This study is for people with a type of kidney cancer (clear cell renal cell carcinoma) that has come back during or within 2 years after finishing a certain kind of immunotherapy (anti-PD-[L]1). The goal is to test if combining different experimental drugs is safe and can shrink…

This study tests a new drug called GI-101, either alone or with pembrolizumab or lenvatinib, in people with advanced solid tumors (cancers that have spread). The goal is to see if it is safe and works against the cancer. About 317 adults with certain cancers like lung, kidney, or…

This study looks at how well the drug T-DXd works in adults with advanced HER2-positive solid tumors that have spread and are not responding to other treatments. About 100 people will be followed to see if their tumors shrink and how long that lasts. The goal is to provide a trea…

This study tests whether giving two drugs (pembrolizumab and axitinib) before surgery can shrink tumor-related blood clots in the main vein of people with kidney cancer. The goal is to make surgery easier and safer, and to improve long-term outcomes. About 17 adults with clear ce…

This study tests a new way to deliver radiation therapy for people with lung cancer, melanoma, or kidney cancer that has started to grow in a few new spots while on other treatments. The approach uses a PET scan to find the most active parts of the tumor and deliver a higher radi…

This study tests whether giving focused radiation to a few growing cancer spots can help people with advanced kidney cancer stay on their current immunotherapy longer. About 30 adults whose cancer has progressed in 1 to 5 spots while on immunotherapy will receive radiation to tho…

This early-phase study tests a new experimental treatment called VET3-TGI, a virus designed to attack cancer cells. It is given alone or with an immunotherapy drug (atezolizumab) to about 60 adults with advanced solid tumors that have not responded to standard treatments. The mai…

This study tests alectinib, a drug already approved for some lung cancers, in patients with rare cancers that have an ALK gene change. About 30 adults and children with ALK-positive cancers will receive alectinib to see if it shrinks tumors or stops them from growing. The goal is…

This early-phase trial tests a new drug called JANX008 in adults with advanced solid tumors (like lung, kidney, breast, or colorectal cancer) that have stopped responding to standard treatments. The main goals are to check safety, find the right dose, and see if the drug can shri…

This study tests whether a combination of two drugs (belzutifan and zanzalintinib) works better than the standard drug cabozantinib for people with advanced kidney cancer that came back after previous treatment. About 904 participants will be randomly assigned to one of the two t…

This early-phase study tests a new treatment called IDOV-Immune, a virus designed to infect and kill cancer cells while boosting the immune system. It is for adults with advanced solid tumors (like colorectal, pancreatic, or lung cancer) that have not responded to standard treatm…

This study tests whether a combination of three drugs (nivolumab, ipilimumab, and cabozantinib) can stop or slow the growth of kidney cancer that has spread to the brain. About 20 adults with untreated brain metastases will receive the drugs. The goal is to see if this approach i…

This early-stage trial tests a new oral drug, DCC-2812, in about 60 people with advanced kidney, bladder, or prostate cancer that has spread or stopped responding to standard treatments. The main goals are to check safety and find the right dose, while also watching for any tumor…

This study tests whether a combination of three drugs—bevacizumab, erlotinib, and atezolizumab—can shrink or stabilize advanced kidney cancer in people with a rare inherited form (HLRCC) or sporadic papillary kidney cancer. The drugs work by cutting off the tumor's blood supply, …

This study tests a new treatment called A2B395 for adults with advanced solid tumors (like colorectal, lung, breast, and kidney cancers) that have not responded to standard therapy. The treatment uses specially engineered immune cells designed to kill cancer cells while protectin…

This study tests an experimental oral drug called NEO212 in people with certain brain tumors (astrocytoma, glioblastoma) or cancers that have spread to the brain. The goal is to find the safest dose and see if it helps control the disease. About 134 adults will take part across t…

This study tests whether giving two immunotherapy drugs (cemiplimab and fianlimab) before surgery for kidney cancer is safe and practical. It involves 10 adults with locally advanced clear cell renal cell carcinoma who are scheduled for a nephrectomy (kidney removal). Researchers…

This study tests two investigational drugs, pembrolizumab alone or with lenvatinib, given before and after kidney cancer surgery. The goal is to see how these drugs affect the immune system's ability to fight the cancer. About 30 adults with high-risk kidney cancer will participa…

This study is testing whether combining two drugs, Envafolimab and Lenvatinib, can shrink tumors in people with advanced solid tumors like lung, kidney, or liver cancer. About 170 adults whose cancer has worsened after standard treatments will receive the drug combination. The go…

This study is for people with kidney cancer that got worse after immunotherapy. It tests a special type of radiotherapy (multimodal radiotherapy) to see if it can control the cancer better. About 35 participants will receive this treatment, and doctors will monitor tumor shrinkag…

This study explores whether kidneys containing small, low-risk tumors can be safely used for transplantation after the tumor is removed. It involves 5 donors over age 50 with small kidney tumors who wish to donate, and recipients with kidney failure. The goal is to increase the n…

This early-stage study tests a new drug called NEO-811 in people with advanced clear cell kidney cancer that cannot be removed by surgery. About 30 participants who have tried other treatments or cannot take them will receive the drug to see if it is safe and what dose works best…

This study is testing whether a combination of three drugs—sasanlimab, palbociclib, and axitinib—can shrink or control advanced kidney cancer that has spread. About 25 adults with clear cell or translocation renal cell carcinoma will receive the drugs and be monitored for tumor r…

This early-stage study tests a new drug called BMS-986506 in people with advanced clear cell kidney cancer that has not responded to prior treatments. The main goal is to check the drug's safety and find the right dose. About 125 participants will take the drug alone to see if it…

This study tests a new combination of two drugs (retifanlimab and ruxolitinib) in people with advanced lung or kidney cancer whose disease got worse after standard immunotherapy. The main goal is to find the safest dose of ruxolitinib when given with retifanlimab, and to see if t…

This early-phase study tests a new drug that delivers radiation directly to cancer cells in people with advanced solid tumors (like lung, colon, head and neck, pancreatic, stomach, or kidney cancer) that have stopped responding to standard treatments. The main goals are to check …

This study tests a new drug (HC-7366) combined with an approved drug (belzutifan) in about 80 adults with advanced or spreading kidney cancer. The goal is to find the safest dose and see if the combination shrinks tumors. Participants must have clear cell kidney cancer that canno…

This early-stage study tests a new drug, QXL138AM, for safety in about 100 people with advanced solid tumors (like ovarian, pancreatic, lung, or breast cancer) or multiple myeloma. Participants must have tried other treatments without success. The study will find the right dose a…

This study is for people with kidney cancer who cannot have surgery or other local treatments. It uses a precise type of radiation called proton beam therapy to target the tumor while aiming to protect the kidney. Researchers will track how well the kidney works after treatment a…

This study looks at whether using ice slush to cool the kidney during robot-assisted partial nephrectomy (surgery to remove part of the kidney) helps the kidney recover from the temporary loss of blood flow. About 310 adults with kidney cancer will take part. The goal is to see i…

This study is testing new types of PET scans to see if they can better find and stage kidney cancer. Researchers will use special tracers that target specific markers on cancer cells. The study involves 66 adults with suspected or confirmed kidney cancer, as well as healthy volun…

This study tests whether contrast-enhanced ultrasound (CEUS) can better detect kidney cancer that has returned after ablation treatment. About 210 adults who had cryotherapy or microwave therapy for kidney cancer will get CEUS scans. The goal is to see if CEUS finds recurrences m…

This study compares a new radiation technique called lattice radiation therapy (LRT) to standard stereotactic body radiation therapy (SBRT) for people with solid tumors that have spread to soft tissues. The goal is to see if LRT shrinks tumors better and helps immune cells attack…

This study looks at whether giving the cancer drug nivolumab as a shot at home is as good as getting it at the clinic. About 50 adults with various cancers will try both ways to see which they prefer and how it affects their quality of life. The goal is to reduce the time, cost, …

This study compares giving cancer treatment at home versus in a clinic for 27 adults with various cancers in the Florida Panhandle. The goal is to see if patients prefer home care and if it is safe. Participants will receive their usual cancer drugs either at home or in the clini…

This study tests a special PET/CT scan that uses a radioactive tracer called [18F]PT2385 to see kidney cancer in more detail. It is not a treatment—it is an exploratory imaging study. About 35 adults with kidney cancer will get the scan, and some will also have a biopsy to compar…

This study tests whether a combined PET/MR scan can better tell aggressive kidney cancers from slow-growing or harmless tumors. About 97 adults with a suspicious kidney mass will get one extra scan during their regular MRI. The goal is to reduce unnecessary surgeries by improving…

This study looks at how often a specific gene change (BAP1 mutation) is found in people with certain cancers like eye melanoma, skin melanoma, kidney cancer, and others. Researchers will study 500 patients and their family members to understand cancer patterns and risk factors. T…

This study looks at how kidney and bladder cancers use nutrients like sugar and fat to grow. About 600 adults having surgery or a biopsy will receive a special nutrient tracer through an IV. Blood and tissue samples are then analyzed to see how the cancer uses these fuels. Partic…

This study is testing whether a simple blood test that looks for cancer DNA can detect if kidney cancer has come back after surgery, possibly earlier than standard imaging scans. Researchers will follow 450 people who have just been diagnosed with kidney cancer and are having sur…

This study is a registry that collects information from about 1,930 people with advanced kidney or bladder cancer in Germany. Researchers will track what treatments patients actually receive, how their disease responds, and their quality of life over time. The goal is to understa…

This study looks at whether people with certain cancers prefer getting their immunotherapy (nivolumab or pembrolizumab) as a shot under the skin or as an IV drip. About 880 patients will try both methods and say which they like better. The goal is to understand patient preference…

This study is for people with certain advanced cancers (like lung, head and neck, or esophageal cancer) who are already scheduled to receive immunotherapy (PD-1/PD-L1 inhibitors). Researchers want to see if adding radiation therapy improves outcomes and, more importantly, if chan…

This study aims to better understand inherited forms of kidney and urinary tract cancers, like Von Hippel-Lindau disease. Researchers will observe families with these conditions over time to learn how the diseases develop, what symptoms they cause, and how specific genetic change…